{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T19:41:05Z","timestamp":1707939665971},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.1007\/s11912-000-0092-y","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T20:56:46Z","timestamp":1180817806000},"page":"182-191","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: Potential for nonablative preparative regimens"],"prefix":"10.1007","volume":"2","author":[{"given":"Richard","family":"Champlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"92_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361\u20131392.","journal-title":"Blood"},{"key":"92_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-4608(96)00246-4","volume":"94","author":"J Dierlamm","year":"1997","unstructured":"Dierlamm J, Michaux L, Criel A, et al.: Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet and Cytogenet 1997, 94:27\u201335.","journal-title":"Cancer Genet and Cytogenet"},{"key":"92_CR3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2141.1996.d01-1478.x","volume":"92","author":"E Matutes","year":"1996","unstructured":"Matutes E, Oscier D, Garcia-Marco J, et al.: Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996, 92:382\u2013388.","journal-title":"Br J Haematol"},{"key":"92_CR4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","volume":"323","author":"G Juliusson","year":"1990","unstructured":"Juliusson G, Oscier DG, Fitchett M, et al.: Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990, 323:720\u2013724.","journal-title":"N Engl J Med"},{"key":"92_CR5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198312293092601","volume":"309","author":"A Arnold","year":"1983","unstructured":"Arnold A, Cossman J, Bakhshi A, et al.: Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid malignancies. N Engl J Med 1983, 309:1593\u20131598.","journal-title":"N Engl J Med"},{"key":"92_CR6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM198509263131303","volume":"313","author":"TA Waldmann","year":"1985","unstructured":"Waldmann TA, Davis MM, Bongiovanni KF, Korsmeyer SJ: T cell antigen receptor gene rearrangements serve as markers of lineage and clonality in human lymphoid neoplasms. N Engl J Med 1985, 313:776\u2013783.","journal-title":"N Engl J Med"},{"key":"92_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.V72.1.353.353","volume":"72","author":"DC Tkachuk","year":"1988","unstructured":"Tkachuk DC, Griesser H, Takihara Y, et al.: Rearrangement of T-cell delta locus in lymphoproliferative disorders. Blood 1988, 72:353\u2013357.","journal-title":"Blood"},{"key":"92_CR8","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood.V78.11.3021.3021","volume":"78","author":"D Billadeau","year":"1991","unstructured":"Billadeau D, Blackstadt M, Greipp P, et al.: Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991, 78:3021\u20133029.","journal-title":"Blood"},{"key":"92_CR9","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","volume":"88","author":"D Provan","year":"1996","unstructured":"Provan D, Bartlett-Pandite L, Zwicky C, et al.: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228\u20132235.","journal-title":"Blood"},{"key":"92_CR10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.1983.1.9.517","volume":"1","author":"ED Thomas","year":"1983","unstructured":"Thomas ED: Bone marrow transplantation for malignant disease. J Clin Oncol 1983, 1:517.","journal-title":"J Clin Oncol"},{"key":"92_CR11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(84)92009-9","volume":"2","author":"RP Gale","year":"1984","unstructured":"Gale RP, Champlin RE: How does bone marrow transplantation cure leukemia? Lancet 1984, 2:28\u201330.","journal-title":"Lancet"},{"key":"92_CR12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"PL Weiden","year":"1981","unstructured":"Weiden PL, Sullivan KM, Flournoy N, et al., for The Seattle Marrow Transplant Team: Antileukemic effect of chronic graftversus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529\u20131532.","journal-title":"N Engl J Med"},{"key":"92_CR13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555\u2013562. A comprehensive analysis of clinical evidence supporting graft-versusleukemia effects","journal-title":"Blood"},{"key":"92_CR14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM198903303201303","volume":"320","author":"KM Sullivan","year":"1989","unstructured":"Sullivan KM, Storb R, Buckner CD, et al.: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989, 320:828\u2013834.","journal-title":"N Engl J Med"},{"key":"92_CR15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","volume":"19","author":"KW Besien Van","year":"1997","unstructured":"Van Besien KW, De Lima M, Giralt SA, et al.: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997, 19:977\u2013982.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","volume":"77","author":"RJ Jones","year":"1991","unstructured":"Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991, 77:649\u2013653.","journal-title":"Blood"},{"key":"92_CR17","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","volume":"84","author":"V Ratanatharathorn","year":"1994","unstructured":"Ratanatharathorn V, Uberti J, Karanes C, et al.: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma. Blood 1994, 84:1050\u20131055.","journal-title":"Blood"},{"key":"92_CR18","first-page":"371","volume":"17","author":"J Mehta","year":"1996","unstructured":"Mehta J, Powles R, Singhal S, et al.: Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996, 17:371\u2013375.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR19","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.1995.13.5.1096","volume":"13","author":"KW Besien van","year":"1995","unstructured":"van Besien KW, Khouri IF, Giralt SA, et al.: Allogeneic bone marrow transplantation for refractory and recurrent lowgrade lymphoma: the case for aggressive management. J Clin Oncol 1995, 13:1096\u20131102.","journal-title":"J Clin Oncol"},{"key":"92_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(97)89488-0","volume":"100","author":"KW Besien van","year":"1996","unstructured":"van Besien KW, Mehra RC, Giralt SA, et al.: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. Am J Med 1996, 100:299\u2013307.","journal-title":"Am J Med"},{"key":"92_CR21","first-page":"669","volume":"18","author":"G Rond\u00f3n","year":"1996","unstructured":"Rond\u00f3n G, Giralt S, Huh Y, et al.: Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996, 18:669\u2013672. First report of graft-versus-malignancy in chronic lymphocytic leukemia, a response to donor lymphocyte infusion.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041\u20132050. First large-scale comprehensive analysis of donor lymphocyte infusions for induction of graft-versus-malignancy effects.","journal-title":"Blood"},{"issue":"suppl 1","key":"92_CR23","first-page":"49","volume":"7","author":"E Goulmy","year":"1991","unstructured":"Goulmy E, Voogt P, Van Els C, et al.: The role of minor histocompatibility antigens in GVHD and rejection: a mini-review. Bone Marrow Transplant 1991, 7(suppl 1):49\u201351.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.174.1.27","volume":"174","author":"JHF Falkenburg","year":"1991","unstructured":"Falkenburg JHF, Goselink HM, Van der Harst D, et al.: Growth inhibition of clonogeneic leukemic precursor cells by minor histocompatibility antigen specific cytotoxic T lymphocytes. J Exp Med 1991, 174:27\u201333.","journal-title":"J Exp Med"},{"key":"92_CR25","first-page":"548","volume":"25","author":"PG Beatty","year":"1997","unstructured":"Beatty PG: National heart, lung, and blood institute (NHLBI) workshop on the importance of minor histocompatibility antigens in marrow transplantation. Exper Hematol 1997, 25:548\u2013558.","journal-title":"Exper Hematol"},{"key":"92_CR26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4049\/jimmunol.149.5.1788","volume":"149","author":"M Beuger De","year":"1992","unstructured":"De Beuger M, Bakker A, van Rood JJ, et al.: Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte defined non-MHC antigens. J Immunol 1992, 149:1788\u20131794.","journal-title":"J Immunol"},{"key":"92_CR27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJM199602013340510","volume":"334","author":"NA Kernan","year":"1996","unstructured":"Kernan NA, Dupont B: Minor histocompatibility antigens and marrow transplantation. N Engl J Med 1996, 334:323\u2013324.","journal-title":"N Engl J Med"},{"key":"92_CR28","first-page":"1514","volume":"21","author":"PG Beatty","year":"1993","unstructured":"Beatty PG: Minor histocompatibility antigens. Exper Hematol 1993, 21:1514\u20131516.","journal-title":"Exper Hematol"},{"key":"92_CR29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood.V76.7.1269.1269","volume":"76","author":"C Perreault","year":"1990","unstructured":"Perreault C, D\u00e9cary F, Brochu S, et al.: Minor histocompatibility antigens. Blood 1990, 76:1269\u20131280.","journal-title":"Blood"},{"key":"92_CR30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1084\/jem.173.1.101","volume":"173","author":"WAF Marijt","year":"1991","unstructured":"Marijt WAF, Veenhof WFJ, Brand A, et al.: Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells. J Exp Med 1991, 173:101\u2013109.","journal-title":"J Exp Med"},{"key":"92_CR31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","volume":"12","author":"IF Khouri","year":"1994","unstructured":"Khouri IF, Keating MJ, Vriesendorp HM, et al.: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994, 12:748\u2013758.","journal-title":"J Clin Oncol"},{"key":"92_CR32","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1182\/blood.V90.10.4201","volume":"90","author":"LF Verdonck","year":"1997","unstructured":"Verdonck LF, Dekker AW, Lokhorst HM, et al.: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin\u2019s lymphoma. Blood 1997, 90:4201\u20134205.","journal-title":"Blood"},{"key":"92_CR33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V67.3.770.770","volume":"67","author":"HG Klingemann","year":"1986","unstructured":"Klingemann HG, Storb R, Fefer A: Bone marrow transplantation in patients aged 45 years and older. Blood 1986, 67:770\u2013776.","journal-title":"Blood"},{"key":"92_CR34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1997.15.1.18","volume":"15","author":"CR Kusnierz-Glaz","year":"1997","unstructured":"Kusnierz-Glaz CR, Schlegel PG, Wong RM, et al.: Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol 1997, 15:18\u201325.","journal-title":"J Clin Oncol"},{"key":"92_CR35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.1993.03510010063030","volume":"270","author":"O Ringd\u00e9n","year":"1993","unstructured":"Ringd\u00e9n O, Horowitz MM, Gale RP, et al.: Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993, 270:57\u201360.","journal-title":"JAMA"},{"key":"92_CR36","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1200\/JCO.1996.14.4.1327","volume":"14","author":"CB Miller","year":"1996","unstructured":"Miller CB, Piantadosi S, Vogelsang GB, et al.: Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996, 14:1327\u20131332.","journal-title":"J Clin Oncol"},{"key":"92_CR37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-104-5-671","volume":"104","author":"RE Champlin","year":"1986","unstructured":"Champlin RE, Gale RP, Foon KA, Golde DW: Chronic leukemias: oncogenes, chromosomes and advances in therapy. Ann Intern Med 1986, 104:671\u2013688.","journal-title":"Ann Intern Med"},{"key":"92_CR38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V85.2.307.307","volume":"85","author":"S O\u2019Brien","year":"1995","unstructured":"O\u2019Brien S, Del Giglio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995, 85:307\u2013318.","journal-title":"Blood"},{"key":"92_CR39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-113-7-525","volume":"113","author":"KA Foon","year":"1990","unstructured":"Foon KA, Rai KR, Gale RP: Chronic lymphocytic leukemia: new insights into biology and therapy. Ann Intern Med 1990, 113:525\u2013539.","journal-title":"Ann Intern Med"},{"key":"92_CR40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.1994.tb01874.x","volume":"53","author":"J Jurlander","year":"1994","unstructured":"Jurlander J, Hartmann Geisler C, Hansen MM: Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 1994, 53:114\u2013118.","journal-title":"Eur J Haematol"},{"key":"92_CR41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","volume":"319","author":"C Bunch","year":"1988","unstructured":"Bunch C: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med 1988, 319:902\u2013907.","journal-title":"N Engl J Med"},{"key":"92_CR42","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V82.8.2379.2379","volume":"82","author":"L Lagneaux","year":"1993","unstructured":"Lagneaux L, Delforge A, Dorval C, et al.: Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production. Blood 1993, 82:2379\u20132385.","journal-title":"Blood"},{"key":"92_CR43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.1981.tb02727.x","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet JL, Catovsky D, Chandra P, et al.: Chronic lymphocytic leukemia: proposals for a revised prognostic staging system. Br J Hematol 1981, 48:365\u2013367.","journal-title":"Br J Hematol"},{"key":"92_CR44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219\u2013234.","journal-title":"Blood"},{"key":"92_CR45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0889-8588(18)30497-0","volume":"4","author":"KR Rai","year":"1990","unstructured":"Rai KR, Han T: Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 1990, 4:447\u2013456.","journal-title":"Hematol Oncol Clin North Am"},{"key":"92_CR46","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990\u20134997. Guidelines for evaluation and treatment of patients with chronic lymphocytic leukemia.","journal-title":"Blood"},{"key":"92_CR47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.bloodjournal74119","volume":"74","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, Kantarjian H, Talpaz M, et al.: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989, 74:19\u201325.","journal-title":"Blood"},{"key":"92_CR48","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","volume":"81","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, O\u2019Brien S, Kantarjian H, et al.: Long-term followup of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993, 81:2878\u20132884.","journal-title":"Blood"},{"key":"92_CR49","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","volume":"82","author":"S O\u2019Brien","year":"1993","unstructured":"O\u2019Brien S, Kantarjian H, Beran M, et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993, 82:1695\u20131700.","journal-title":"Blood"},{"key":"92_CR50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.1991.9.1.44","volume":"9","author":"MJ Keating","year":"1991","unstructured":"Keating MJ, Kantarjian H, O\u2019Brien S, et al.: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991, 9:44\u201349.","journal-title":"J Clin Oncol"},{"key":"92_CR51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","volume":"15","author":"PJ Bierman","year":"1997","unstructured":"Bierman PJ, Vose JM, Anderson JR, et al.: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 1997, 15:445\u2013450.","journal-title":"J Clin Oncol"},{"key":"92_CR52","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V82.4.1366.1366","volume":"82","author":"SN Rabinowe","year":"1993","unstructured":"Rabinowe SN, Soiffer RJ, Gribben JG, et al.: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993, 82:1366\u20131376.","journal-title":"Blood"},{"key":"92_CR53","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.V84.3.957.957","volume":"84","author":"ST Traweek","year":"1994","unstructured":"Traweek ST, Slovak ML, Nademanee AP, et al.: Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Blood 1994, 84:957\u2013963.","journal-title":"Blood"},{"key":"92_CR54","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2141.1997.272673.x","volume":"97","author":"IF Khouri","year":"1997","unstructured":"Khouri IF, Przepiorka D, van Besien K, et al.: Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997, 97:466\u2013473.","journal-title":"Br J Haematol"},{"key":"92_CR55","first-page":"619","volume":"6","author":"E Montserrat","year":"1992","unstructured":"Montserrat E, Gale RP, Rozman C: Bone marrow transplants for chronic lymphocytic leukemia. Leukemia 1992, 6:619\u2013622.","journal-title":"Leukemia"},{"key":"92_CR56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","volume":"124","author":"M Michallet","year":"1996","unstructured":"Michallet M, Archimbaud E, Bandini G, et al.: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996, 124:311\u2013315.","journal-title":"Ann Intern Med"},{"issue":"suppl 5","key":"92_CR57","first-page":"31","volume":"20","author":"CM Croce","year":"1993","unstructured":"Croce CM: Molecular biology of lymphomas. Semin Oncol 1993, 20(suppl 5):31\u201346.","journal-title":"Semin Oncol"},{"key":"92_CR58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V80.4.879.879","volume":"80","author":"SJ Korsmeyer","year":"1992","unstructured":"Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80:879\u2013886.","journal-title":"Blood"},{"issue":"suppl 5","key":"92_CR59","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ: Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol 1993, 20(suppl 5):75\u201388.","journal-title":"Semin Oncol"},{"key":"92_CR60","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1991.9.5.762","volume":"9","author":"JE Romaguera","year":"1991","unstructured":"Romaguera JE, McLaughlin P, North L, et al.: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991, 9:762\u2013769.","journal-title":"J Clin Oncol"},{"key":"92_CR61","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","volume":"12","author":"A L\u00f3pez-Guillermo","year":"1994","unstructured":"L\u00f3pez-Guillermo A, Montserrat E, Bosch F, et al.: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994, 12:1343\u20131348.","journal-title":"J Clin Oncol"},{"key":"92_CR62","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-114-10-855","volume":"114","author":"P Litam","year":"1991","unstructured":"Litam P, Swan F, Cabanillas F, et al.: Prognostic value of serum b-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991, 114:855\u2013860.","journal-title":"Ann Intern Med"},{"issue":"suppl 5","key":"92_CR63","first-page":"89","volume":"20","author":"B Coiffier","year":"1993","unstructured":"Coiffier B, Bastion Y, Berger F, et al.: Prognostic factors in follicular lymphomas. Semin Oncol 1993, 20(suppl 5):89\u201395.","journal-title":"Semin Oncol"},{"key":"92_CR64","first-page":"51","volume":"17","author":"CS Portlock","year":"1990","unstructured":"Portlock CS: Management of the low-grade non-Hodgkin\u2019s lymphomas. Semin Oncol 1990, 17:51\u201359.","journal-title":"Semin Oncol"},{"key":"92_CR65","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.1992.10.6.942","volume":"10","author":"DJ Weisdorf","year":"1992","unstructured":"Weisdorf DJ, Andersen JW, Glick JH, Oken MM: Survival after relapse of low-grade non-Hodgkin\u2019s lymphoma: implications for marrow transplantation. J Clin Oncol 1992, 10:942\u2013947.","journal-title":"J Clin Oncol"},{"key":"92_CR66","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.1995.13.7.1734","volume":"13","author":"MA Rodriguez","year":"1995","unstructured":"Rodriguez MA, Cabanillas FC, Velasquez W, et al.: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995, 13:1734\u20131741.","journal-title":"J Clin Oncol"},{"key":"92_CR67","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE, et al.: Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996, 14:1262\u20131268.","journal-title":"J Clin Oncol"},{"key":"92_CR68","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","volume":"325","author":"JG Gribben","year":"1991","unstructured":"Gribben JG, Freedman AS, Neuberg D, et al.: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991, 325:1525\u20131533.","journal-title":"N Engl J Med"},{"key":"92_CR69","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","volume":"12","author":"AZS Rohatiner","year":"1994","unstructured":"Rohatiner AZS, Johnson PWM, Price CGA, et al.: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994, 12:1177\u20131184.","journal-title":"J Clin Oncol"},{"key":"92_CR70","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V85.11.3334.bloodjournal85113334","volume":"85","author":"RS Negrin","year":"1995","unstructured":"Negrin RS, Kusnierz-Glaz CR, Still BJ, et al.: Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin\u2019s lymphoma. Blood 1995, 85:3334\u20133341.","journal-title":"Blood"},{"key":"92_CR71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"PWM Johnson","year":"1995","unstructured":"Johnson PWM, Rohatiner AZS, Whelan JS, et al.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995, 13:140\u2013147.","journal-title":"J Clin Oncol"},{"key":"92_CR72","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.1994.12.12.2535","volume":"12","author":"RM Stone","year":"1994","unstructured":"Stone RM, Neuberg D, Soiffer R, et al.: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol 1994, 12:2535\u20132542.","journal-title":"J Clin Oncol"},{"key":"92_CR73","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V83.12.3780.3780","volume":"83","author":"JS Miller","year":"1994","unstructured":"Miller JS, Arthur DC, Litz CE, et al.: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994, 83:3780\u20133786.","journal-title":"Blood"},{"key":"92_CR74","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1994.12.12.2527","volume":"12","author":"DL Darrington","year":"1994","unstructured":"Darrington DL, Vose JM, Anderson JR, et al.: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994, 12:2527\u20132534.","journal-title":"J Clin Oncol"},{"key":"92_CR75","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1200\/JCO.1991.9.10.1848","volume":"9","author":"JH Lundberg","year":"1991","unstructured":"Lundberg JH, Hansen RM, Chitambar CR, et al.: Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 1991, 9:1848\u20131859.","journal-title":"J Clin Oncol"},{"key":"92_CR76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bmt.1700904","volume":"20","author":"EJ Dann","year":"1997","unstructured":"Dann EJ, Daugherty CK, Larson RA: Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 1997, 20:369\u2013374.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR77","first-page":"591","volume":"12","author":"JD Shepherd","year":"1993","unstructured":"Shepherd JD, Barnett MJ, Connors JM, et al.: Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 1993, 12:591\u2013596.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR78","first-page":"150","volume":"3","author":"K Besien van","year":"1997","unstructured":"van Besien K, Thall P, Korbling M, et al.: Allogeneic transplantation for recurrent or refractory non-Hodgkin\u2019s lymphoma with poor prognostic features after conditioning with thiotepa, busulfan and cyclophosphamide: experience in 44 consecutive patients. Biol Blood and Marrow Transplant 1997, 3:150\u2013156.","journal-title":"Biol Blood and Marrow Transplant"},{"key":"92_CR79","first-page":"1832","volume":"92","author":"K Besien van","year":"1998","unstructured":"van Besien K, Sobocinski K, Rowlings PA, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998, 92:1832\u20131836. A large International Bone Marrow Transplant Registry analysis of allogeneic bone marrow transplantation for treatment of advanced low-grade lymphoma.","journal-title":"Blood"},{"key":"92_CR80","first-page":"1120a","volume":"93","author":"M Attal","year":"1997","unstructured":"Attal M, Soci\u00e9 G, Molina L, et al.: Allogeneic bone marrow transplantation for refractory and recurrent follicular lymphoma: a case-matched analysis with autologous transplantation from the French bone marrow transplant group registry data [abstract]. Blood 1997, 93:1120a.","journal-title":"Blood"},{"key":"92_CR81","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","volume":"89","author":"LH Argatoff","year":"1997","unstructured":"Argatoff LH, Connors JM, Klasa RJ, et al.: Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997, 89:2067\u20132078.","journal-title":"Blood"},{"key":"92_CR82","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","volume":"16","author":"W Hiddemann","year":"1998","unstructured":"Hiddemann W, Unterhalt M, Hermann R, et al.: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade lymphoma study group. J Clin Oncol 1998, 16:1922\u20131930.","journal-title":"J Clin Oncol"},{"key":"92_CR83","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1997.15.4.1664","volume":"15","author":"A Majlis","year":"1997","unstructured":"Majlis A, Pugh WC, Rodriguez MA, et al.: Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997, 15:1664\u20131671.","journal-title":"J Clin Oncol"},{"key":"92_CR84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","volume":"16","author":"AS Freedman","year":"1998","unstructured":"Freedman AS, Neuberg D, Gribben JG, et al.: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation in mantlecell lymphoma: no evidence for long-term remission. J Clin Oncol 1998, 16:13\u201318.","journal-title":"J Clin Oncol"},{"key":"92_CR85","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803\u20133809.","journal-title":"J Clin Oncol"},{"key":"92_CR86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bmt.1701044","volume":"21","author":"D Adkins","year":"1998","unstructured":"Adkins D, Brown R, Goodnough LT, et al.: Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998, 21:97\u201399.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2141.1996.d01-1816.x","volume":"94","author":"P Corradini","year":"1996","unstructured":"Corradini P, Ladetto M, Astolfi M, et al.: Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol 1996, 94:376\u2013378.","journal-title":"Br J Haematol"},{"key":"92_CR88","first-page":"2642a","volume":"90","author":"I Khouri","year":"1997","unstructured":"Khouri I, Romaguera J, Kantarjian H, et al.: Mantle cell lymphoma: improved outcome with hyper-CVAD\/high-dose methotrexate-cytarabine (MTX-Ara-C) followed by autologous or allogeneic stem cell transplantation [abstract]. Blood 1997, 90:2642a.","journal-title":"Blood"},{"key":"92_CR89","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","volume":"328","author":"JO Armitage","year":"1993","unstructured":"Armitage JO: Drug therapy: treatment of non-Hodgkin\u2019s lymphoma. N Engl J Med 1993, 328:1023\u20131030.","journal-title":"N Engl J Med"},{"key":"92_CR90","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","volume":"327","author":"LI Gordon","year":"1992","unstructured":"Gordon LI, Harrington D, Andersen J, et al.: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin\u2019s lymphoma. N Engl J Med 1992, 327:1342\u20131349.","journal-title":"N Engl J Med"},{"key":"92_CR91","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 1993, 328:1002\u20131006.","journal-title":"N Engl J Med"},{"key":"92_CR92","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin\u2019s lymphoma. N Engl J Med 1995, 333:1540\u20131545.","journal-title":"N Engl J Med"},{"key":"92_CR93","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","volume":"316","author":"T Philip","year":"1987","unstructured":"Philip T, Armitage JO, Spitzer G, et al.: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med 1987, 316:1493\u20131498.","journal-title":"N Engl J Med"},{"key":"92_CR94","first-page":"549","volume":"15","author":"K Besien Van","year":"1995","unstructured":"Van Besien K, Tabocoff J, Rodriguez M, et al.: High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995, 15:549\u2013555.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.1991.9.2.211","volume":"9","author":"B Coiffier","year":"1991","unstructured":"Coiffier B, Gisselbrecht C, Vose JM, et al.: Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991, 9:211\u2013219.","journal-title":"J Clin Oncol"},{"key":"92_CR96","first-page":"2291","volume":"89","author":"M Engelhard","year":"1997","unstructured":"Engelhard M, Brittinger G, Huhn D, et al.: Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997, 89:2291\u20132297.","journal-title":"Blood"},{"key":"92_CR97","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1995.13.3.575","volume":"13","author":"JF Seymour","year":"1995","unstructured":"Seymour JF, Talpaz M, Cabanillas F, et al.: Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995, 13:575\u2013582.","journal-title":"J Clin Oncol"},{"key":"92_CR98","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V74.2.558.558","volume":"74","author":"B Coiffier","year":"1989","unstructured":"Coiffier B, Lepage E: Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989, 74:558\u2013564.","journal-title":"Blood"},{"key":"92_CR99","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V83.5.1165.1165","volume":"83","author":"MA Shipp","year":"1994","unstructured":"Shipp MA: Prognostic factors in aggressive non-Hodgkin\u2019s lymphoma: who has \"high-risk\" disease. Blood 1994, 83:1165\u20131173.","journal-title":"Blood"},{"key":"92_CR100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/oxfordjournals.annonc.a058324","volume":"3","author":"J Rodriguez","year":"1992","unstructured":"Rodriguez J, Cabanillas F, McLaughlin P, et al.: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the \"tumor score.\" Ann Oncol 1992, 3:711.","journal-title":"Ann Oncol"},{"key":"92_CR101","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 1993, 329:987\u2013995. International index of clinical prognostic factors for predicting outcome of therapy for lymphoma.","journal-title":"N Engl J Med"},{"key":"92_CR102","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1987.5.9.1340","volume":"5","author":"FR Appelbaum","year":"1987","unstructured":"Appelbaum FR, Sullivan KM, Buckner CD, et al.: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 1987, 5:1340\u20131347.","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"92_CR103","first-page":"9","volume":"14","author":"KG Blume","year":"1994","unstructured":"Blume KG, Long GD, Negrin RS, et al.: Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994, 14(suppl 4):9\u201310.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR104","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.1995.13.3.596","volume":"13","author":"T Demirer","year":"1995","unstructured":"Demirer T, Weaver CH, Buckner CD, et al.: High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior doselimiting radiation therapy. J Clin Oncol 1995, 13:596\u2013602.","journal-title":"J Clin Oncol"},{"key":"92_CR105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.1986.4.4.480","volume":"4","author":"GL Phillips","year":"1986","unstructured":"Phillips GL, Herzig RH, Lazarus HM, et al.: High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 1986, 4:480\u2013488.","journal-title":"J Clin Oncol"},{"key":"92_CR106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/10428199509056853","volume":"17","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Nath R, Ippoliti C, et al.: A Phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995, 17:427\u2013433.","journal-title":"Leuk Lymphoma"},{"key":"92_CR107","first-page":"767","volume":"14","author":"T Witte de","year":"1994","unstructured":"de Witte T, Awwad B, Boezeman J, et al.: Role of allogeneic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant 1994, 14:767\u2013774.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR108","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1200\/JCO.1990.8.5.809","volume":"8","author":"X Troussard","year":"1990","unstructured":"Troussard X, Leblond V, Kuentz M, et al.: Allogeneic bone marrow transplantation in adults with Burkitt\u2019s lymphoma or acute lymphoblastic leukemia in first complete remission. J Clin Oncol 1990, 8:809\u2013812.","journal-title":"J Clin Oncol"},{"key":"92_CR109","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","volume":"10","author":"R Chopra","year":"1992","unstructured":"Chopra R, Goldstone AH, Pearce R, et al.: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin\u2019s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 1992, 10:1690\u20131695. Large case-control study in which allogeneic transplants produced similar survival to autologous transplantation. The lower relapse rate with allogeneic transplantation was offset by a higher rate of treatment-related mortality.","journal-title":"J Clin Oncol"},{"key":"92_CR110","doi-asserted-by":"crossref","first-page":"1124a","DOI":"10.1182\/blood.V90.3.1124","volume":"90","author":"AJ Peniket","year":"1997","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival has not risen because of higher treatment-related mortality\u2014a report of 764 cases from the EBMT lymphoma registry. Blood 1997, 90:1124a.","journal-title":"Blood"},{"key":"92_CR111","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V85.6.1655.bloodjournal8561655","volume":"85","author":"WI Bensinger","year":"1995","unstructured":"Bensinger WI, Weaver CH, Appelbaum FR, et al.: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655\u20131658.","journal-title":"Blood"},{"key":"92_CR112","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.V85.6.1659.bloodjournal8561659","volume":"85","author":"M Korbling","year":"1995","unstructured":"Korbling M, Przepiorka D, Huh YO, et al.: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995, 85:1659\u20131665.","journal-title":"Blood"},{"key":"92_CR113","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bmt.1700692","volume":"19","author":"D Przepiorka","year":"1997","unstructured":"Przepiorka D, Anderlini P, Ippoliti C, et al.: Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997, 19:455\u2013460.","journal-title":"Bone Marrow Transplant"},{"key":"92_CR114","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1097\/00007890-199612270-00022","volume":"62","author":"D Przepiorka","year":"1996","unstructured":"Przepiorka D, Ippolitti C, Khouri I, et al.: Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation 1996, 62:1806\u20131810.","journal-title":"Transplantation"},{"key":"92_CR115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","volume":"10","author":"D Przepiorka","year":"1999","unstructured":"Przepiorka D, Van Besian K, Khouri I, et al.: Etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999, 10:527\u2013532.","journal-title":"Ann Oncol"},{"key":"92_CR116","first-page":"784","volume":"8","author":"T Philip","year":"1988","unstructured":"Philip T, Hartman O, Brian P, et al.: High dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy for diffuse non-Hodgkin\u2019s lymphoma. J Clin Oncol 1988, 8:784\u2013791.","journal-title":"J Clin Oncol"},{"key":"92_CR117","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0889-8588(05)70108-8","volume":"13","author":"R Champlin","year":"1999","unstructured":"Champlin R, Khouri I, Kornblau S, et al.: Allogeneic hematopoietic transplantation as adoptive immunotherapy: induction of graft-vs-malignancy as primary therapy. Hematol Oncol Clin North Am 1999, 13:1041\u20131057. Summary of concepts of nonablative preparative regimens for allogeneic hematopoietic transplantation.","journal-title":"Hematol Oncol Clin North Am"},{"key":"92_CR118","first-page":"54","volume":"1","author":"RE Champlin","year":"1997","unstructured":"Champlin RE, Khouri I, Giralt S: Induction of graft-vs-leukemia as a therapeutic modality. ASCO Education Book 1997, 1:54\u201358.","journal-title":"ASCO Education Book"},{"key":"92_CR119","first-page":"621","volume":"3","author":"RE Champlin","year":"1999","unstructured":"Champlin RE, Khouri I, Kornblau S, et al.: Reinventing bone marrow transplantation: nonmyeloablative preparative regimens and induction of graft-vs-malignancy effects. Oncology 1999, 3:621\u2013628.","journal-title":"Oncology"},{"key":"92_CR120","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","volume":"10","author":"JR Redman","year":"1992","unstructured":"Redman JR, Cabanillas F, Velasquez WS, et al.: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992, 10:790\u2013794.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"92_CR121","first-page":"301a","volume":"88","author":"I Khouri","year":"1996","unstructured":"Khouri I, Keating MJ, Przepiorka D, et al.: Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia [abstract]. Blood 1996, 88(suppl 1):301a.","journal-title":"Blood"},{"key":"92_CR122","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","volume":"16","author":"I Khouri","year":"1998","unstructured":"Khouri I, Keating M, Korbling M, et al.: Transplant lite: induction of graft-versus-leukemia using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817\u20132824. Initial report of nonmyeloablative hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma.","journal-title":"J Clin Oncol"},{"key":"92_CR123","first-page":"1553a","volume":"94","author":"I Khouri","year":"1999","unstructured":"Khouri I, Lee M-S, Palmer L, et al.: Transplant-lite using fludarabine-cyclophosphamide and allogeneic stem cell transplantation for low grade lymphoma [abstract]. Blood 1999, 94:1553a.","journal-title":"Blood"},{"key":"92_CR124","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","volume":"86","author":"S Mackinnon","year":"1995","unstructured":"Mackinnon S, Papadopoulos EB, Carabasi MH, et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261\u20131268.","journal-title":"Blood"},{"key":"92_CR125","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337","volume":"86","author":"S Giralt","year":"1995","unstructured":"Giralt S, Hester J, Huh Y, et al.: CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft vs leukemia without graft vs. host disease. Blood 1995, 86:4337\u20134343.","journal-title":"Blood"},{"key":"92_CR126","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","volume":"276","author":"C Bonini","year":"1997","unstructured":"Bonini C, Ferrari G, Verzeletti S, et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graftversus-leukemia. Science 1997, 276:1719\u20131724.","journal-title":"Science"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-000-0092-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-000-0092-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-000-0092-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T19:01:37Z","timestamp":1707937297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-000-0092-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s11912-000-0092-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}